- Home
- CARM vs IBIO Comparison
CARM vs IBIO Comparison
Compare CARM & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- IBIO
- Stock Information
- Founded
- CARM 2016
- IBIO 2008
- Country
- CARM United States
- IBIO United States
- Employees
- CARM N/A
- IBIO N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CARM Health Care
- IBIO Health Care
- Exchange
- CARM Nasdaq
- IBIO Nasdaq
- Market Cap
- CARM 12.2M
- IBIO 11.9M
- IPO Year
- CARM N/A
- IBIO N/A
- Fundamental
- Price
- CARM $0.34
- IBIO $0.89
- Analyst Decision
- CARM Hold
- IBIO Strong Buy
- Analyst Count
- CARM 5
- IBIO 2
- Target Price
- CARM $0.90
- IBIO $5.50
- AVG Volume (30 Days)
- CARM 25.7M
- IBIO 2.0M
- Earning Date
- CARM 11-06-2025
- IBIO 11-11-2025
- Dividend Yield
- CARM N/A
- IBIO N/A
- EPS Growth
- CARM N/A
- IBIO N/A
- EPS
- CARM N/A
- IBIO N/A
- Revenue
- CARM $10,767,000.00
- IBIO $400,000.00
- Revenue This Year
- CARM N/A
- IBIO N/A
- Revenue Next Year
- CARM N/A
- IBIO N/A
- P/E Ratio
- CARM N/A
- IBIO N/A
- Revenue Growth
- CARM N/A
- IBIO 77.78
- 52 Week Low
- CARM $0.14
- IBIO $0.56
- 52 Week High
- CARM $1.27
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- CARM 50.22
- IBIO 54.48
- Support Level
- CARM $0.34
- IBIO $0.77
- Resistance Level
- CARM $0.39
- IBIO $0.97
- Average True Range (ATR)
- CARM 0.06
- IBIO 0.05
- MACD
- CARM 0.00
- IBIO -0.04
- Stochastic Oscillator
- CARM 35.74
- IBIO 90.77
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.